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High-intensity focused ultrasound (HIFU) competes with radiofrequency and cryotherapy for the treatment of small renal masses
as a third option among ablative approaches. As an emerging technique, its possible percutaneous or laparoscopic application,
low discomfort to the patient and the absence of complications make this technology attractive for the management of small
renal masses. This manuscript will focus on the principles, basic research and clinical applications of HIFU in small renal masses,
reviewing the present literature. Therapeutic results are controversial and from an clinical view, HIFU must be considered a tech-
nique under investigation at present time. Further research is needed to settle its real indications in the management of small renal
masses; maybe technical improvements will certainly facilitate its use in the management of small renal masses in the near future.
Copyright © 2008 Jose Rubio Briones et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
We are facing a rapid increase of incidentally detected small
r e n a lm a s s e s( S R M s )n o w a d a y s[ 1, 2], prompting us to face
many diﬀerent clinical scenarios and probably minimally
invasive ablative techniques will ﬁnd their role in those unﬁt
patients who are not operable and do not accept a partial
nephrectomy or a watchful waiting policy [3]i nc a s eo f
a possible renal cell carcinoma (RCC) diagnosed probably
incidentally [4].
High-intensity focused ultrasound (HIFU) induces ther-
mal damage to the targeted tissue without the need of the
insertion of a probe into the tissue, thus being the most real
“minimally invasive” proposed technique among the ablative
treatments for small renal masses (SRMs).
This manuscript will focus on the principles, basic
research, and clinical applications of HIFU in small renal
masses, reviewing the present literature and analyzing HIFU
as a possible treatment for SRM, recognizing no experience
in its use for any renal masses by our group.
2. MATERIAL AND METHODS
We reviewed PubMed with no limit on time, searching for
papers in English or Spanish, using HIFU and renal or
HIFU and kidney as key words. We included the literature
published on HIFU both in the experimental and clinical
settings.
3. PRINCIPLES AND TECHNIQUE
The principle of HIFU resembles the one for ultrasound
(US), but a higher intensity is used. Ultrasound is pro-
gressively absorbed by the tissue and its mechanical energy
converted to heat. At a high and focused strategy, the
generated heat denatures proteins and produces coagulative
necrosis,objectivesobtainedwhentemperaturereaches65
◦C
in renal lesions [5]. The induction of thermal necrosis
will depend on several factors: the applied power, the US
frequency, transducer characteristics (shape, type, size, and
number of probes), exposure time, spatial distribution of
the ﬁeld, absorption properties of the tissue, attenuation in
the intervening tissue, acoustic reﬂection and refraction, and
ﬁnally the perfusion rate in the targeted tissue. Diﬀerent
necrosis rates were shown (volume of ablated tissue per 1
secondisonication)fordiﬀerentorgans,andforexample,the
kidney has a lower necrosis rate than the liver [6].
Asatechnique underdevelopment, therearenostandard
recommendationsforitsapplicationandthisisapointunder
vast research. Initially, extracorporeal HIFU generators used2 Advances in Urology
multiple piezoelectric elements located in a concave disk,
generating intensities of >10000W/cm2 w h i c hw e r ed e r i v e d
in cavitation lesions, limitating its use in humans [7].
Nowadays, HIFU systems use single transducers, focused by
acoustic lenses or by being concave. As the focal lengths
are smaller, frequencies of 3-4MHz can be achieved, pro-
ducing smaller but better deﬁned lesions. Modern HIFU
devices obtain focal depths of 10–16cm; the focal zones
are cigar shaped and the volume ablated depends on power
intensity, duration of application, and location of pulses.
All this equipment is accompanied by US regular probes
trying to control the eﬀectiveness of the HIFU application;
interestingly, as power intensity increases (5–20kW/cm2),
a cavitation phenomenon appears which permits a target
point to monitor HIFU eﬀects [8]. An excellent summary on
physical principles and devices of HIFU [9]h a sr ec e n t l ybee n
published.
In the extracorporeal approach, frequencies of 1–
1.8MHz are used in an attempt to increase penetration; in
this range, renal thermal lesions were observed in animal
models [10, 11]. In the clinical setting, two systems for
extracorporeal HIFU have been tested. First, from Storz
Medical (Storz; Schaﬀhausen, Switzerland), we use a 1MHz
piezo element focused at a depth of 100mm with a parabolic
reﬂector of 10cm aperture. An integrated 3.5MHz B-mode
UStransducerpermitsinlineimagingoftheareatotreat.The
US beam is coupled into the body by a ﬂexible polyurethane
cushion ﬁlled with degassed water at 16
◦C, witch permits
the variation of the skin-focal spot distance altering its ﬁlling
[12]. The second HIFU therapeutic system was designed by
Chonqing Haifu CO. Ltd (Chonqing, China); it is composed
byapatienttable,anoperatingconsole,andatreatmentunit,
situated under the table within a basin ﬁlled with degassed
water to couple with US delivered to the patient, who lies
over the water bath. Exchangeable ellipsoidal transducers of
12 or 15cm diameter are installed in the water bath around
acentral3.5MHzdiagnostictransducer.Thissystempermits
frequenciesof0.5,1.2,and1.5MHzandfocallengthsof100–
160mm depending on the transducer used. Following the
treatment protocol and by exposing the targeted areas up to
six times, the authors achieve an estimated site intensity of
up to 20000W/cm2, enough to create cavitation and even
bubble formation on real-time diagnostic imaging, which
authors propose as successful tissue ablation marker [13].
Due to the problems with extracorporeal HIFU appli-
cations that we will further comment on, the equipment
moved into the laparoscopic ﬁeld. In porcine models, it
was modiﬁed with acceptable partial kidney ablation with
no damage to surrounding not targeted tissues [14]. In
phase I study, this approach was attempted in the human
setting, using conventional lap isolation of the SRM through
four 12mm access ports; authors used intraoperative renal
power Doppler US with a 10Hz laparoscopic US probe
(BK Medical, Denmark) to locate the SRM. They then
changed one of the ports to an 18mm port (Ethicon; San
Angelo,Tx,USA)tointroducethelaparoscopicHIFUsystem
(Sonatherm, Misonix Inc., Fiarmigdale, NY, USA), which
is composed by a treatment console, an articulated probe
arm, a pomp unit, and the laparoscopic probe (covered with
a system which permits cooling with gas-free cold water)
[15]. HIFU energy is delivered by a truncated spherical shell
4MHz transducer with a 30 × 13mm aperture and a 35mm
focal length. One of the best improvements of this approach,
compared to the percutaneous one, is that the probe works
in direct contact with the SRM and real-time imaging, based
on qualitative assess on hyperechoic changes resulting from
boiling and cavitation events, permitting direct control of
the procedure with the 12mm transducer aligned confocally
with the HIFU transducer. The procedure was calibrated
resembling the results obtained in animal models research
to ablate tissue at an average rate of 0.6cm3/min at typical
power level between 30–38W [14, 16].
4. RESULTS
We found 42 manuscripts using HIFU and renal/kidney
as key words. HIFU has been extensively used in other
organs, targeted to malignant and nonmalignant tissues:
brain, breast, eye, prostate, bladder, uterus, liver, and so
forth, showing no increase in cell dissemination [17–20]. An
attractive indication for tumour in a solitary testis has been
recently published with acceptable results [21].
4.1. Pathologicalassessment
The thermal damage produced by HIFU causes progressive
tissue changes depending on the time when the patholog-
ical study is done. Immediately after its application in a
porcine model, the tissue demonstrated intense congestion,
hyperaemia, and alterations of the micropapillaries, and
electronmicroscopyshowedalterationsofthemitochondria,
ribosomes, and lysozymes. At day 2, necrosis starts to be
seen within an intense area of hyperaemia and congestion
which results in complete necrosis at day 7. Finally, at day
90, a complete ﬁbrosis of the targeted area is observed
[22]. On healthy human kidney, haemorrhages were seen
in 15 out of 19 cases and microscopically, it was shown
that they were caused by ﬁbre ruptures in the wall of
small vessels [23]. In papers where SRMs have been excised
after HIFU application, “severe thermal tissue damage”
has been deﬁned as intravascular disruption of erythrocyte
membranes, vacuolisation of tumour and arterial smooth
muscle cells, pycnosis and elongation of tumour cell nuclei,
rupture of tumour cell membranes, and cell detachment,
changes which correspond to complete tissue necrosis if the
time elapsed from HIFU application and specimen removal
is longer [24]. Negative NADH staining in snap-frozen
tissue obtained before tissue ﬁxation with formaldehyde
after HIFU treatment also reaﬃrms irreversible heat damage
[15, 24].
4.2. Resultsinthepercutaneousapproach
Linke et al. were the ﬁrst to treat a kidney of a rabbit using
extracorporeal HIFU [25]. When applied percutaneously in
a rabbit model, it was clearly showed that only 2 out of 9
tumours showed well-demarcated eﬀects of ablation [26].
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detected in 67% [11]. In a canine model, HIFU application
with 400W power and 4-second pulse duration and a
calculated site intensity of 1430W/h obtained coagulative
necrosis of variable degree in the targeted area [12]. Recently,
the use of microbubbles injected before percutaneous HIFU
isonication of goat kidneys showed better necrosis rates than
direct HIFU application [13].
In humans, phase II study using the Storz system
was conducted by the University of Vienna. Sixteen renal
tumours were treated with HIFU, two with curative intent
and 14 were subsequently removed. Examination of the
specimens showed poor results in terms of therapeutic eﬀect,
as necrosis was found only in 9 out of 14 cases, all of which
had been exposed to the highest site intensities, and the
histologically damaged tissue only composed 15–35% of the
targeted tissue [27]. In another phase II study, H¨ acker et al.
treated 19 patients with RCC before nephrectomy, focusing
HIFU to healthy renal tissue; after immediate removal of the
kidney, they observed variable but limited pathological signs
of thermal damage, as for example haemorrhages, just in 15
out of 19 specimens, but these eﬀects could not be correlated
totheenergyadministeredandlesionsizedidneverreachthe
targeted volume [23].
When using the Chongqing system, Wu et al. applied
percutaneous HIFU with a palliative intent in 13 advanced
RCC, having shown clinical improvement (less pain and
disappearanceofhaematuria)inmostofthetreatedpatients,
althoughtreatmentwasconsideredincompletein10patients
[18]. Similar disappointing results were published from UK,
where 8 patients were treated with a similar system and
only 4 out of 6 kidneys showed radiological evidence of
treatment eﬀect on MRI 12 days after HIFU application
and just 1 out of 4 removed kidneys showed histological
conﬁrmed ablation [17]. This group is currently undergoing
a prospective, nonrandomized clinical trial of percutaneous
HIFU in the treatment of SRM, looking at histological
outcome in resected tumours in one arm and following the




HIFU approach previously described was applied to 10
patients with solitary renal masses. Two of them had 9cm
tumours and HIFU was applied just as marker lesion before
radical laparoscopic nephrectomy; the rest had SRM with
a median size of 22mm and were treated with a “curative
intent” applying HIFU to the entire tumour with a margin of
2-3mmofsurroundingparenchyma.Sevenofthesetumours
were operated afterwards by means of a laparoscopic partial
nephrectomy and one was left in situ in a patient with
high comorbidities. In the SRM subgroup, a median HIFU
exposure time of 19 minutes (range 8–42) was used. The
ﬁrst two patients showed, in the subsequent pathological
examination, just a 2-3mm of vital tissue adjacent to where
the HIFU probe was approximated with the rest of the
tumour with thermal necrosis; the authors explained this
phenomenon to an excessive cooling of the probe, and
changing this parameter, they did not observe it again in the
remaining cases, although a patient showed a 20% central
area with no thermal eﬀects, showing complete thermal
necrosis in the 4 remaining removed cases (57%). The
nonexcisedtumourwassuccessfullytreatedattendingtoreal-
time US data, examination of core biopsies showing thermal
necrosis,andfollow-upCTscansupto6monthsshowingno
constraint enhancement and shrinking of the lesion [15].
4.4. Complications
There have been just two severe complications due to
HIFU application in the abdominal cavity in humans: a
superiormesentericarteryinfarctionandaperforationofthe
terminal ileum, but both were after treatment of recurrent or
metastatic colon carcinoma [29]. When focused to kidneys,
no serious side eﬀects have been shown [27]; just 2 patients
had grade III skin lesions [28], but the most common type of
skin toxicity is less than 1cm blister or track at the treatment
site [17]. Changes in laboratory tests are also nonsigniﬁcant
[17, 18].
5. DISCUSSION
Technology has improved the initial problems of the ﬁrst
HIFU intents to treat kidneys with devices derived from
piezoelectric lithotripters [22] which could not focus the tar-
geted lesion; the development of a new HIFU source (Storz
UTT System, Storz Medical AG, Kreuzlingen, Switzerland)
with a smaller (10cm) diameter for ﬂexible extracorporeal
application permitted the authors to focus precisely on the
targeted area in an ex vivo scenario with perfused kidneys,
adjusting the pulse duration and the power of the generator
to the lesion size [30].
One of the major problems with HIFU is that from
an extracorporeal application, there are several factors that
interfere between the power emitted by the ultrasound probe
and the energy arriving to the targeted area: focal length,
type, and characteristics of the tissue to be crossed through
variable vascularization of the kidney and its mobility as well
asthelimitationproximityofair(gut)orbone(ribs)because
of reverberation, acoustic shadowing, and refraction [31],
the last with burning power with potential damage to close
organs.
Another drawback of percutaneous HIFU application
is the absence of a reliable radiologic method controlling
the eﬀects of HIFU in real time. Research is being done
to ﬁnd more ﬁxed devices coupled with respiratory move-
ments trying to save absorption of ultrasound energy from
nontargeted tissues like ribs, fat, or muscles; MRI is being
more extensively proposed as a guide to the treatment
compared with regular ultrasound due to its information
regarding temperature changes in the treated tissue within
seconds after application [31]. Unfortunately, movement of
the kidney also aﬀects the accuracy of MRI thermometry
[32]. Mobility has been partly corrected using multichannel
focused US systems, trying to combine motion tracking
and feedback electronic steering of the HIFU beam [33]
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transducers that also theoretically permit more ﬂexible
targeting [34, 35].
All these reasons could explain the poor results in the
clinical setting, mostly when histopathological assessment of
thermal necrosis on the targeted tissue has been studied. The
limited clinical experience with the extracorporeal approach
and its poor results make this approach not suitable to
treat renal cancer in humans, and it has to be considered a
technique under experimental research [12].
Although percutaneous approach would be the ideal
and real “no invasive,” laparoscopic approach facilitates
resolutions of many of the problems facing the percutaneous
approach. The use of the 18mm laparoscopic HIFU trans-
ducer, applicable to conventional lap armamentarium and
controlled by US, as shown by Klingler et al. in phase I study,
indicated just for peripheral tumours not larger than 3.5cm
in size [15], opens a window to clinical research with this
method as it really does not clamp the kidney or puncture
it as other ablative techniques. Although the protocol is
under evolution, the authors have shown safe and promising
results with at least better thermal necrosis results than those
obtained with the percutaneous approach, but it has to be
kept in mind that laparoscopy itself is not complication-
free as it needs general anaesthesia, pneumoperitoneum, and
tumour isolation, so this approach will have to be compared
in randomized trials with other nonablative techniques and
also with watchful waiting policies in front of SRM in elderly
or unﬁt patients, the subgroup of patients where it makes
sense to avoid open or laparoscopic partial nephrectomy for
an SRM.
The follow-up of SRM treated with HIFU is gener-
ally performed by contrast-enhanced CT and MRI, but
other methods such as PET and microbubble contrast-
enhanced ultrasound are under evaluation [36]. Microbub-
bles increased the ablation eﬃciency and the visibility of tis-
sue destruction attending to the appearance of hyperechoic
regions within the targeted tissue [6]. As with the rest of the
nonablative techniques, deﬁnitive follow-up protocols are
missing [37], and the role of the biopsy in contrast-enhanced
lesions has to be investigated [38].
One of the advantages of HIFU applications is that
treatments could be repeated, but the need to do it under
general anaesthesia results in a limitation of this strategy.
Vast research is needed to establish standards of pulse
and power levels which ascertain tissue death, as well as the
number and types of probes utilized, as in ex vivo porcine
experiments, at identical power levels, lesions induced by
multiple probes were larger than those induced by single
probe [34]. Another nonresolved issue is the ﬁnal extent of
the coagulative thermal-induced necrosis with time. Finally,
extracorporeal or laparoscopic approach will have to deﬁne
their advantages.
Thus, to establish the clinical usefulness of HIFU to
treat SRM, long-term follow-up studies are needed taking
into account recurrence-free survival data, quality of life
parameters, complications and cost analysis, and all these
data compared in clinical trials with open or laparoscopic
partial nephrectomy as gold standard techniques [39],
cryotherapy and radiofrequency as minimally invasive more
developed techniques [40], and watchful waiting policy [3]
as options to manage small renal masses.
6. CONCLUSIONS
HIFU is a promising approach to treat SRM because it is
probably the most minimally invasive among the proposed
techniques. Nevertheless, the number of treated patients is
very small, and its results with the percutaneous approach
make it not applicable to the humans with a curative
intent. Laparoscopic approach makes it a loose part of its
“minimally invasive” principles, but preliminary data show
better thermal necrosis results and better US real-time
control of the treatment. For the moment, we think that
HIFU has to be considered as an investigational technique.
Technical improvements could certainly facilitate its use in
the management of SRM in the near future.
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